NASDAQ:MITO
Delisted

Stealth Biotherapeutics Stock Signals

etoro logo Buy MITO
*Your capital is at risk
$0.320
+0 (+0%)
At Close: Feb 14, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for Stealth BioTherapeutics Corp

General

Signal Type Signal Value Data
Score 0.000 82 days ( -0.98 %
Last Price $0.320 0 %
Performance History
7 Days
$0.320 $0.320
0%
30 Days
$0.320 $0.320
0%
12 Mos
$0.626 $0.320
-48.87%

8/18

Active Buy Signals

Specific Signals

Short Term
Net score: 59.46
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.320 - $0.320
Trend - 3 mos 0 % High Width: 0.0302 %
Pred. range - 3 mos $0.320 - $0.320 Low -0.0283 % - 0.0019 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Sell Very Low Feb 13, 2023 - 2 days
RSI Short Pivot Signal Buy Very Low Dec 02, 2022 - 50 days
Short MA 3 mos Buy Low Nov 22, 2022 - 57 days
Long MA 3 mos Buy Medium Jan 04, 2023 - 29 days
Short/Long MA 3 mos Buy Medium Jan 04, 2023 - 29 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 59.84
Signal Type Signal Value Importance Data
Trend - 12 mos -30.23 % Very High Width: 6,923.59 %
Pred. range - 12 mos $0.0052 - $0.363 High -98.38 % - 13.53 %
Short MA 12 mos Buy Very High Nov 30, 2022 - 52 days
Long MA 12 mos Buy Very High Aug 24, 2022 - 120 days
Short/Long MA 12 mos Buy Very High Aug 25, 2022 - 119 days
Pivot Long Sell Low Nov 04, 2022 - 69 days
RSI Long Pivot Signal Buy Low Dec 13, 2022 - 43 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT STEALTH BIOTHERAPEUTICS CORP
Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for th...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE